Wade Williams, MD
Pulmonary Disease · Shawnee Mission, KSNPI 1588757967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,662 and has fallen 94.2% since, to $97 in 2025.
Across 200 payments — averaging $15.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$702
- AstraZeneca$358
- Boehringer Ingelheim$357
- Sunovion Pharmaceuticals Inc.$257
- Genentech USA, Inc.$218
- Grifols USA, LLC$198
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,07899%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $702 |
| AstraZeneca | 18 | $358 |
| Boehringer Ingelheim | 20 | $357 |
| Sunovion Pharmaceuticals Inc. | 19 | $257 |
| Genentech USA, Inc. | 14 | $218 |
| Grifols USA, LLC | 12 | $198 |
| Insmed, Inc. | 10 | $164 |
| Philips North America LLC | 7 | $127 |
| Teva Pharmaceuticals USA, Inc. | 9 | $121 |
| Mallinckrodt Enterprises LLC | 4 | $107 |
| Pulmonx Corporation | 2 | $49 |
| Intuitive Surgical | 1 | $41 |
| EMD Serono, Inc. | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Advanced Respiratory, Inc | 2 | $36 |
| Sanofi | 2 | $34 |
| Covis Pharma GmbH | 2 | $31 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Resmed Corp | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Amgen | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| AbbVie | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $14 |
| Electromed, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| SK Life Science, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$3,101 in reported general payments places this provider in the 55th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 275 | $263,561 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $90,202 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $75,284 |
| XolairOmalizumab | 11 | $60,011 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 77 | $59,314 |
| Dupixent PenDupilumab | 13 | $56,272 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 65 | $42,071 |
| Spiriva HandihalerTiotropium Bromide | 11 | $16,942 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 88 | $14,943 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 53 | $12,505 |
| DuleraMometasone/Formoterol | 22 | $10,588 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $9,175 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $8,801 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $8,472 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $7,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $702 | $413,077503 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $358 | $91,104122 claims |
| Boehringer IngelheimStiolto Respimat, Combivent Respimat | $357 | $51,24676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Shawnee Mission
- Brandon BowersShawnee Mission$22K
- Montgomery RobertsShawnee Mission$4K
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Robert SourkHutchinson$33K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.